Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7781131 | 0.80 | L3MBTL1 (0.34) | DPP7L3MBTL1 | |
| SCHEMBL27858121 | 0.78 | L3MBTL1 (0.34) | L3MBTL1CYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL9435781 | 0.77 | SLC29A1 (0.32) | CYP1A2MAPK1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL28023530 | 0.76 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL27888800 | 0.75 | DPP7 (0.47) | DPP7CYP1A2 | |
| SCHEMBL27888798 | 0.75 | DPP7 (0.47) | DPP7CYP1A2 | |
| SCHEMBL3053925 | 0.74 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL6768696 | 0.74 | MEN1 (0.34) | CYP1A2SMN1; SMN2ALDH1A1 | |
| SCHEMBL2919950 | 0.74 | — | — | |
| SCHEMBL28197631 | 0.72 | HRH3 (0.35) | L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223776-B2 | Compounds with anti-bacterial activity | MORPHOCHEM AG (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20060040949-A1 | Novel compounds with antibacterial activity | MORPHOCHEM AG | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040949-A1 | Novel compounds with antibacterial activity | MRPL21, Q6ZSR9, MRPL19 | DPP7 342/4885L3MBTL1 3171/4885CYP1A2 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.